✦ LIBER ✦

Pharmacokinetic Screening ofo-Naphthoquinone 5-Lipoxygenase Inhibitors

✍ Scribed by Ashok Rakhit; Steve K. Kuwahara; David R. Jones; Victor F. Soliman; Alvin N. Kotake; Thomas D. Oglesby; Jan W. F. Wasley; Spencer L. Tripp; Frank L. Douglas

Book ID: 110343472
Publisher: Springer US
Year: 1990
Tongue: English
Weight: 846 KB
Volume: 07
Category: Article
ISSN: 0724-8741
DOI: 10.1023/a:1015903519637

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P40 Antioxidative properties of a naphth

P40 Antioxidative properties of a naphthoquinone 5-lipoxygenase inhibitor

✍ Wurm, G. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies

✍ K. Marr; K. Marsh; L. Hernandez; F.M. Cunningham; P. Lees 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 981 KB

ChemInform Abstract: Syntheses of 4-(3,5

ChemInform Abstract: Syntheses of 4-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,2-naphthoquinones, Potential 5-Lipoxygenase Inhibitors.

✍ G. WURM 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 30 KB 👁 2 views

Pharmacokinetics of a novel 5-lipoxygena

Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma

✍ S. L. Wong; G. L. Kearns; J. P. Kemp; J. Drajesk; M. Chang; C. S. Locke; L. M. D 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 103 KB

Population pharmacokinetics of zileution

Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis

✍ W. M. Awni; G. R. Granneman; C. S. Locke; S. R. Brandwein; L. M. Dube 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 653 KB

The pharmacokinetics of zileuton, a novel selective 5-1ipoxygenase inhibitor, were studied in 37 patients with rheumatoid arthritis after administration of 200 mg, 400 rag, and 600 mg zileuton for 4 weeks. Patients had 6-h pharmacokinetic evaluation of zileuton on day 14. Plasma zileuton concentrati

Dose-proportional pharmacokinetics of a

Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers

✍ Shekman L. Wong; Jeffrey Drajesk; Min S. Chang; Galen Witt; Walid M. Awni 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

, a new potent 5-lipoxygenase inhibitor, is under development for the treatment of asthma. The pharmacokinetics and dose proportionality of ABT-761 after single doses (10 -160 mg) of ABT-761 in 24 healthy male volunteers were investigated in a double-blind, placebo-controlled study. The compound was